Abstract
A series of experiments has been performed in healthy male volunteers to investigate the disposition of orally administered disodium azodisalicylate, a potentially useful drug for the treatment of ulcerative colitis. The drug was given by mouth in doses of up to 2 g a day for six weeks and there were no adverse effects. Serum concentrations of the intact compound were low and the serum half-time was 4-12.8 days, probably because of a combination of a low clearance rate and a high apparent volume of distribution. Less than 5% of the ingested dose was excreted unchanged in the urine. Circulating concentrations of 5-ASA and N-acetyl-5-ASA were low and 30% of the equivalent daily dose was excreted in the urine, predominantly as N-acetyl-5-ASA. In most subjects more than 30% of the equivalent daily dose of 5-ASA was recovered from the faeces, either as 5-ASA itself or as the acetylated derivative. As 5-ASA has been shown to be the active therapeutic moiety of sulphasalazine, disodium azodisalicylate appears to be suitable for therapeutic trial in ulcerative colitis.
Full text
PDF






Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Azad Khan A. K., Howes D. T., Piris J., Truelove S. C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980 Mar;21(3):232–240. doi: 10.1136/gut.21.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
- Azadkhan A. K., Truelove S. C., Aronson J. K. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol. 1982 Apr;13(4):523–528. doi: 10.1111/j.1365-2125.1982.tb01415.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- BARON J. H., CONNELL A. M., LENNARD-JONES J. E., JONES F. A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962 May 26;1(7239):1094–1096. doi: 10.1016/s0140-6736(62)92080-9. [DOI] [PubMed] [Google Scholar]
- DICK A. P., GRAYSON M. J., CARPENTER R. G., PETRIE A. CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS. Gut. 1964 Oct;5:437–442. doi: 10.1136/gut.5.5.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Das K. M., Eastwood M. A., McManus J. P., Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973 Sep 6;289(10):491–495. doi: 10.1056/NEJM197309062891001. [DOI] [PubMed] [Google Scholar]
- Dissanayake A. S., Truelove S. C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut. 1973 Dec;14(12):923–926. doi: 10.1136/gut.14.12.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Peppercorn M. A., Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology. 1973 Feb;64(2):240–245. [PubMed] [Google Scholar]
- Schröder H., Campbell D. E. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539–551. doi: 10.1002/cpt1972134539. [DOI] [PubMed] [Google Scholar]
- Willoughby C. P., Piris J., Truelove S. C. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol. 1980;15(6):715–719. doi: 10.3109/00365528009181520. [DOI] [PubMed] [Google Scholar]
- van Hees P. A., van Tongeren J. H., Bakker J. H., van Lier H. J. Active therapeutic moiety of sulphasalazine. Lancet. 1978 Feb 4;1(8058):277–277. doi: 10.1016/s0140-6736(78)90524-x. [DOI] [PubMed] [Google Scholar]